Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA
|
|
- Audra Miles
- 6 years ago
- Views:
Transcription
1 6 Clin Oncol Cancer Res () 7: 6-5 DOI.7/s Anti-Tumor Efficacy of Gene Vaccine Expressing PSMA Xiao-ling YANG Jing LV Yue-hong ZHANG Bo NIU, Department of Laboratory Medicine, Shanxi Bo ai Hospital, Taiyuan, Shanxi Province, China. Department of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi Province, China. Biotechnology Research Laboratory, Capital Institute of Pediatrics, Beijing, China. Correspondence to: Bo NIU Tel: OBJECTIVE To observe anti-tumor effects of PVAX-PSMA gene vaccine. METHODS The PSMA gene was inserted into a mammalian expression vector, PVAX-, to construct the DNA vaccine candidate, and was then used to vaccinate C57BL/6 mice. Animals vaccinated with PVAX- and NaCl were used as controls. Anti-PSMA antibody was detected in sera of the animals. The proliferation and cytotoxicity of the spleen cells were observed. The immunized mice were inoculated with RM- cells. The mice were inoculated with RM- cells, and then the mice were immunized. The anti-tumor efficacy of the gene vaccine was evaluated by the ratio of tumor formation, tumor volume, tumor mass before and a er gene vaccination and evaluated by survival rate of the immunized mice. RESULTS High level of anti-psma antibody was induced in the PVAX-PSMA group. The splenocytes from PVAX-PSMA group were stimulated to produce strong proliferation responses and significant cytotoxic T-cells (CTL) activity. After the mice were immunized with PVAX-PSMA gene, tumor occurrence was decreased, and the growth velocity of tumor was markedly reduced, resulting in prolonged tumor-free time (P <.5). CONCLUSION PVAX-PSMA gene vaccine has significant antitumor effects and provides an experimental basis for primary prevention and immunotherapy of prostate cancer. KEY WORDS: prostate cancer, prostate-specific membrane antigen, gene vaccine. Copyright by Tianjin Medical University Cancer Institute & Hospital and Springer Introduction Received August, ; accepted November 6,. 8cocr@gmail.com Tel (Fax): Prostate cancer has the highest incidence rate in men and accounts for 9% of all new cancer diagnosis. In 7, approximately 8,89 new cases of prostate cancer and 7,5 deaths due to prostate cancer were estimated in the US alone []. Early screening to detect prostate has reduced the mortality rate of prostate cancer. The expression level of the prostate specific membrane antigen (PSMA) has been proposed as a useful marker, indicating how late the prostate cancer has been [-5]. PSMA, a type II transmembrane glycoprotein with a Mr of kd, is found in metastatic prostate cancer, hormone refractory tumors, the vascular endothelium of some carcinomas and sarcomas, and limited its expression in normal cells and in benign prostatic
2 Clin Oncol Cancer Res () 7: secretory-acinar epithelium [6,7]. Gene vaccine is a new approach to immunization and immunotherapy. In the years following the publication of the initial demonstration of the ability of plasmid DNA in vivo to generate protective immune responses, DNA vaccines have entered into a variety of clinical trials for vaccines against various infectious diseases and for therapies against cancer. In this study, we introduced the gene encoding the specific antigen PSMA into a mammalian expression vector PVAX- in C57BL/6 mice bearing RM- cells obtained from injection of the tumor cells, for the purpose of observing the anti-tumor effect of the recombinant vaccine. Materials and Methods Materials Forty-five C57BL/6 mice were purchased from the Experimental Animal Center of Shanxi Medical University; recombinant plasmid PVAX-PSMA and RM- cell were produced in our laboratory; eukaryotic expression vector PVAX- was obtained from Invitrogen Co; LDH assay kit was purchased from Promega Co; a large number of ultrapure plasmid kits for fast isolation were purchased from Boda Co; Triton X- was produced by Amresco Co; MTT assay kit was obtained from Promega Co; Mitomycin C was purchased from Sigma. Methods Preparation and purification of recombinant plasmid The plasmid PVAX- and recombinant plasmid PVAX- PSMA were extracted with a large number of ultrapure plasmid kits for fast isolation. Endotoxin in plasmid solution was removed by Triton X- phase separation. Recombinant plasmid was dissolved by sterile saline. The concentration of recombinant plasmid was diluted into g/l with sterile saline. Injection of the plasmid Fifteen C57BL/6 mice were randomly divided into PVAX-PSMA group, PVAX- group and NaCl group (5 in each). Five mg/l of procaine, μl for each were injected into the quadriceps of the mice days before they were immunized. The method of immunization: μl of the recombinants (the concentration of recombinants was g/l) were injected into the quadriceps of each C57BL/6 mouse in the groups at the st, th, and st day. All the experimental procedures and animal maintenance met the strict guidelines of institutional animal ethics committee. Identification of anti-psma antibody in immunized mice Serum was extracted from each mouse in the groups days after each time the mice were immunized, and the extracted serum was preserved at - C. Anti-PSMA antibody was detected through indirect immunofluorescence assay. Proliferation of T lymphocyte in the spleen The spleen cells were obtained from the mice and then prepared into single cell suspension. The stimulated cells were prepared as follows. RM- cells with mitomycin C was cultured at 7 C for h. The ratio of the spleen cells to the stimulated cells was 5:, and they were cultured in a 96-well plate as controls. And then we operated manually the MTT assay kit. Formulation of proliferation index of the Lymphocytes: (A57 value in experiment group A57 value in stimulated cell group)/a57 value in spleen control group. Detection of CTL in immunized mice Killing effect of RM- on spleen cells was detected using LDH assay kit. RM- cells, as target cells were inoculated into a 96-well plate with the density of cells/well, with different amounts of effector cells added in order to reach the ratios of effector cells to target cells being 5:, 5: and :, respectively, and then cultured at 7 C for h. And then we operated manually the LDH assay kit. Formulation of killing rate of CTL: (experiment release-natural release of effector cells natural release of target cells)/(target cell maximum natural release of target cells) %. Establishment of tumor xenografts and assessment of growth There were 5 immunized mice in each group. At the st day, the immunized mice were inoculated. ml of tumor cell, RM- ( /ml) through subcutaneous injection. The process of tumor growth was recorded every week. The length (a) and width (b) of the tumor were measured by caliper regularly. The tumor volume was then calculated by the formula: volume = (a b )/. Preventive effects of gene vaccine Fifteen new mice were divided randomly into the groups, PVAX-PSMA group, PVAX- group and NaCl group. The mice were inoculated. ml tumor cell, RM- ( /ml) through subcutaneous injection. When the tumors grew tactile, μl recombinants (the concentration of the recombinants was g/l) were injected into the quadriceps of each C57BL/6 mouse in the groups at the st, th, and st day. The process of tumor growth was recorded every 8 day. The length (a) and width (b) of the tumor were measured using caliper regularly. The tumor volume was then calculated by the formula: volume = (a b )/. Statistical analysis Results were expressed as Mean ± SD, and one-way analysis of variance (ANOVA) was used for evaluating statistical significance. A value of P <.5 was considered statistically significant.
3 8 Clin Oncol Cancer Res () 7: 6-5 Results Detection of anti-psma antibody There was no anti-psma antibody in the sera of the mice in PVAX- group and NaCl group, but high level of anti-psma antibody was induced in the PVAX-PS- MA group. After the first immunization, antibody titer was :; after the second immunization, antibody titer was :; after the third immunization, antibody titer was :6 (Table ). Moreover, during a period of time, the antibody concentration appeared to go up as the time went by. Detection of proliferation effects on spleen T lymphocytes When the RM- cells with mitomycin C was cultured together, PVAX-PSMA group could induce obvious proliferation effects on spleen lymphocyte. The differences in proliferation rate between the PVAX-PSMA group and each of the control groups were significant (P <.5, Fig.). Detection of CTL When the ratio of effector cells to target cells was 5:, PVAX-PSMA group could induce a effective killing activity of CTL, causing stronger cellular immune response, and its killing rate was 7.%. When contrasted with the killing rate of the CTL in the PVAX-PSMA group, the killing rate in the PVAX- group and in NaCl group was.5% and.8%, respectively. The differences in killing rate between the PVAX-PSMA group and each of the control groups were significant (P <.5, Fig.). Preventive effects of gene vaccine The tumor forming rate was % in both NaCl group and PVAX- group, and was % in PVAX-PSMA group. The tumor in NaCl group and PVAX- group grew fast, and the differences in tumor volume and tumor mass between the PVAX-PSMA group and each of the control groups were significant (P <.5, Table ). In PVAX-PSMA group, tumor-free time was longer and survival rate increased after the mice were inoculated RM-cells compared with the other groups. Therefore, the lifetime of the mice in the PVAX-PSMA group was significantly different than that of the mice in the other control groups (P <.5, Fig.). Anti-tumor effects of the vaccine C57BL/6 mice (5 per group) were first challenged by giving. ml RM- tumor cells ( /ml) subcutaneously. Fifteen days after tumor challenged, the tumor forming rate in each of the groups was %, and the tumor volume was approximate mm. The mice in each of the groups were vaccinated with PVAX- PSMA, PVAX- and NaCl, respectively for times with a -day interval in between. In the NaCl group and PVAX- group, the tumor grew fast. The changes in the tumor volume indicated that PVAX-PSMA could significantly inhibit the growth of RM- cells in vivo. At day 6, the tumor volume in the PVAX-PSMA group was only (.7 ±.8) cm, significantly less than the tumor volume of (.78 ±.) cm in the NaCl group and also less than that of (.6 ±.9) cm in the PVAX- group. The differences in growth velocity of tumor between the PVAX-PSMA group and each of the control groups were significant (P <.5, Fig.). Table. The antibody level in the sera of the mice. Antibody titer After the first immunization After the second immunization After the third immunization NaCl PVAX- Vaccination NaCl PVAX- Vaccination NaCl PVAX- Vaccination : : : : Proliferation index I II III Times of immunization Fig.. The proliferation of spleen T lymphocytes in the C57BL/6 mice. P <.5 compared with NaCl group and PVAX- group. I, NaCl group stimulated by RM- cells; II, PVAX- group stimulated by RM- cells; III, PVAX-PSMA group stimulated by RM- cells. Specificlysis (%) Effector/Target PVAX-PSMA PVAX- N Fig.. Cytotoxicity T-lymphocyte (CTL) assay.
4 Clin Oncol Cancer Res () 7: Survival rate NaCl PVAX- PVAX-PSMA Times after tumor challenge (d) Table. Tumor volume, tumor mass and tumor forming rate in mice after immunotherapy (n = 5, Mean ± SD). Group Tumor volume (cm ) Tumor mass (g) Tumor forming rate (%) NaCl.96 ±. 6. ±.57 PVAX-.88 ± ±. PVAX-PSMA.5 ± ±.8 P <.5 compared with NaCl group and PVAX- group. Fig.. The comparison of mouse survival rate. Tumor volume (cm ) NaCl Tumor volume (cm ) PVAX Tumor volume (cm ) PVAX-PSMA Fig.. Inhibitory effects of the groups on tumor growth in mouse in vivo (n = 5). Discussion Prostate cancer is the most common neoplasia diagnosed in men in developed countries. In this study, we showed for the first time that the tumor biomarker PSMA, a multi-functional cell surface ectopeptidase [], was endowed with an efficient signaling activity in prostate cancer cells. In prostate cancer cells, PSMA is expressed at -fold higher level than in normal prostate epithelium. Expression levels are increased with disease progression, with the highest level in metastatic diseases, hormone refractory cancers, and higher-grade lesions [7]. Endothelial-expression of PSMA in the neovasculature of a variety of non-prostatic solid malignancies has also been detected [8]. Gene vaccine could provide a good therapeutic possibility against tumors. DNA vaccines are simple rings of DNA containing a gene encoding an antigen, and a promoter/terminator to make the gene express in mammalian cells. They are a promising new approach for generating all types of desired immunity: cytolytic T lymphocytes (CTL), T helper cells and antibodies. This study further explored gene therapy of prostate cancer using recombinant plasmid PVAX-PSMA. The key point of gene therapy is to establish an effective gene delivering system. In this study, a highly safe vector PVAX- was selected to construct a recombinant vector. Recombinant plasmid PVAX-PSMA was then used to vaccinate C57BL/6 mice. Animals vaccinated with PVAX- or NaCl were used as controls. The immunized mice were inoculated RM- cells for the purpose of observing the anti-tumor effects of the recombinant vaccine. The mechanisms may be: i) It has been clear for many years that CD + T cells have a key role in helping B cells produce antibody [9]. ii) The majorities of candidate tumor antigens are intracellular and expressed only as peptides in the groove of the MHC class I molecule. Only CD8 + T cells can recognize these peptides and, after recognition, develop into effector CTLs capable of killing the target cells []. In this study, the splenocytes from PVAX-PSMA group were stimulated to produce strong proliferation responses and significant cytotoxic T-cells (CTL) activity. After the mice were immunized with PVAX-PSMA gene, tumor occurrence was decreased, and the growth velocity of tumor was markedly reduced, resulting in prolonged tumor- free time (P <.5). In a word, gene vaccine PVAX-PSMA may provide a feasible and effective way in prostate cancer treatment. Conflict of interest statement No potential conflicts of interest were disclosed.
5 5 Clin Oncol Cancer Res () 7: 6-5 References Jemal A, Siegel R, Ward E, et al. Cancer statistics, 7. CA Cancer J Clin 7; 57:. Rajasekaran AK, Anilkumar G, Christiansen JJ. Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol 5; 88: C975-C98. Chandran SS, Banerjee SR, Mease RC, et al. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 8; 7: Chu TC, Shieh F, Lavery LA, et al. labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 6; : Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J59 in advanced solid tumors. J Clin Oncol 7; 5: Sokoloff RL, Norton KC, Gasior CL, et al. A dualmonoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate ; : 5. 7 Slovin SF. Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen. Expert Opin Ther Targets 5; 9: Chang SS, Reuter VE, Heston WD, et al. Department of Urologic Surgery VUMCNTUSA. Comparison of antiprostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology ; 57: Stevenson FK, Ottensmeier CH, Johnson P, et al. DNA vaccines to attack cancer. Proc Natl Acad Sci U S A. ; : Oxford JS. The end of the beginning: Vaccines for the next 5 years. Vaccine 8; 6:
The Use of Allogeneic Leukocytes Infusion in Cancer Immunotherapy
Research Article The Use of Allogeneic Leukocytes Infusion in Cancer Immunotherapy Yishu Tang 1*, Chunxia Zhou 2, Wenbo Ma 2, Dongmei Wang 2, Shuren Zhang 2 1 Department of Laboratory Medicine, The First
More informationThe humoral immune responses to IBV proteins.
The humoral immune responses to IBV proteins. E. Dan Heller and Rosa Meir The Hebrew University of Jerusalem, Israel COST FA1207 meeting WG2 + WG3, Budapest, Jan. 2015 1 IBV encodes four major structural
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More information1. Overview of Adaptive Immunity
Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive
More informationA549 and A549-fLuc cells were maintained in high glucose Dulbecco modified
Cell culture and animal model A549 and A549-fLuc cells were maintained in high glucose Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum at 37 C in humidified atmosphere containing
More informationCurrent Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a Case Study
Note: I have added some clarifying comments to the slides -- please click on Comments under View to see them. Current Strategies in HIV-1 Vaccine Development Using Replication-Defective Adenovirus as a
More informationThe Major Histocompatibility Complex (MHC)
The Major Histocompatibility Complex (MHC) An introduction to adaptive immune system before we discuss MHC B cells The main cells of adaptive immune system are: -B cells -T cells B cells: Recognize antigens
More informationCANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
More informationWhy chaperone vectors?
Why chaperone vectors? A protein folding initiative An open discussion with structural biologists Protein Structure Initiative: Pilot Phase Whether the pilot phase achieved its goal depends on how we measure
More informationAntigen Presentation to T lymphocytes
Antigen Presentation to T lymphocytes Immunology 441 Lectures 6 & 7 Chapter 6 October 10 & 12, 2016 Jessica Hamerman jhamerman@benaroyaresearch.org Office hours by arrangement Antibodies and T cell receptors
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationZheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY. Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p.
Title Studies of SARS virus vaccines Author(s) Zheng, BJ; Du, LY; Zhao, GY; Lin, YP; Sui, HY; Chan, C; Ma, S; Guan, Y; Yuen, KY Citation Hong Kong Medical Journal, 2008, v. 14 suppl. 4, p. 39-43 Issued
More informationMucosal Immune System
Exam Format 100 points - 60 pts mandatory; 40 points where 4, 10 point questions will be chosen Some open-ended questions, some short answer. Kuby question Cytokines Terminology How do cytokines achieve
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationExpressions of MVD, VEGF, Ki67 in Residual Prostate Cancer after Cryoablation
Clin Oncol Cancer Res (211) 8: 27-32 DOI 1.17/s1185-11-555-y 27 Expressions of MVD, VEGF, Ki67 in Residual Prostate Cancer after Cryoablation Yong LI Zhi GUO Yan-ping HAN Xiu-ying GUO Tianjin Key Laboratory
More informationApproved for Public Release; Distribution Unlimited
AD Award Number: W81XWH-04-1-0186 TITLE: A Novel Therapeutic System for the Treatment of Occult Prostate Cancer PRINCIPAL INVESTIGATOR: Shongyun Dong, M.D., Ph.D. CONTRACTING ORGANIZATION: University of
More informationCanqiu Yu 1, Jinwei Chen 2, Li Huang 3*
A STUDY ON THE ANTITUMOUR EFFECT OF TOTAL FLAVONOIDS FROM PTERIS MULTIFIDA POIR IN H22 TUMOUR-BEARING MICE 459 Canqiu Yu 1, Jinwei Chen 2, Li Huang 3* 1 Department of General Surgery, The Second Xiangya
More informationThis article is downloaded from.
This article is downloaded from http://researchoutput.csu.edu.au It is the paper published as: Author: G.-Y. Li, J.-Z. Liu, S.-G. Chen, C.-B. Wang, B. Zhang and L. Wang Title: Effect of a seashell protein
More informationNKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies
NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies Saul Kivimäe Senior Scientist, Research Biology Nektar Therapeutics NK Cell-Based Cancer Immunotherapy, September 26-27,
More informationClinical Translation of a Mammaglobin A DNA Vaccine for Breast Cancer Therapy
Clinical Translation of a Mammaglobin A DNA Vaccine for Breast Cancer Therapy William E. Gillanders, M.D. Recombinant DNA Advisory Committee December 14, 25 Overview This is a phase I dose ranging vaccine
More informationASSESSMENT OF IMMUNE STABILITY IN BREAST CANCER SUBJECTS
ASSESSMENT OF IMMUNE STABILITY IN BREAST CANCER SUBJECTS Oluboyo, A.O Dr. Department of Medical Laboratory Science, Faculty of Health Sciences and Technology, College of Health Sciences, Nnamdi Azikiwe,
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationPSMA SPECT imaging with 99m. Tc-MIP-1404 in patients with prostate cancer (PCa): Comparison with Bone scan, CT or MRI.
PSMA SPECT imaging with 99m Tc-MIP-1404 in patients with prostate cancer (PCa): Comparison with Bone scan, CT or MRI. Shankar Vallabhajosula, Ph.D., Berna Polack, M.D., Yulia S. Jhanwar, M.D. Anastasia
More informationAnti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study
Anti-prostate cancer effects of CTL cell induction in vitro by recombinant adenovirus mediated PSMA/4-1BBL dendritic cells: an immunotherapy study C.-G. Sui, D. Wu, F.-D. Meng, M.-H. Yang and Y.-H. Jiang
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationMemory NK cells during mousepox infection. Min Fang, Ph.D, Professor Institute of Microbiology, Chinese Academy of Science
Memory NK cells during mousepox infection Min Fang, Ph.D, Professor Institute of Microbiology, Chinese Academy of Science Infectious Diseases are a Major Cause of Death Worldwide May 14 th 1796 Prevalence
More informationThe effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells
The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells Published in: Natl Med J China, February 10, 2003; Vol 83, No 3, Page 195-197. Authors: JIAO Shun-Chang,
More informationSupporting Information
Supporting Information lpek et al. 1.173/pnas.1121217 SI Materials and Methods Mice. cell knockout, inos / (Taconic arms), Rag1 /, INγR /, and IL-12p4 / mice (The Jackson Laboratory) were maintained and/or
More informationChapter 22: The Lymphatic System and Immunity
Bio40C schedule Lecture Immune system Lab Quiz 2 this week; bring a scantron! Study guide on my website (see lab assignments) Extra credit Critical thinking questions at end of chapters 5 pts/chapter Due
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationLAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies
LAMPvax DNA Vaccines as Immunotherapy for Cancer - Three Case Studies Cancer immunotherapy has emerged as a clinically validated tool for fighting certain kinds of cancers. These therapeutic cancer vaccines
More informationCELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.
!! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)
More information1ME A17R11 WI238 DMS2114 JC L2929 P815 PT67
20 1 2004 1 Chinese Journal of Biotechnology Vol. 20 No. 1 January 2004 3 (, 361005), BacV2CMV2EGFPA,Sf9, 20, 12,7,1 CMV,,,LipofectAMINE CMV EGFP pcdna3112egfp, CMV EGFP, CMV CMV,,,,,, Bac2to2Bac 2, CMV,,,
More informationEts-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs
Ets-1 identifying polynucleotide sequence for targeted delivery of anti-cancer drugs Indian Patent Application No. 1623/DEL/2014 Inventors: Prof. Kulbhushan Tikoo and Jasmine Kaur Department of Pharmacology
More informationNature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.
Supplementary Figure 1 Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice. (a) Gene expression profile in the resting CD4 + T cells were analyzed by an Affymetrix microarray
More informationB16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small cell lung cancer
Electronic Supplementary Material (ESI) for ChemComm. This journal is The Royal Society of Chemistry 2017 Experimental Methods Cell culture B16-F10 (Mus musculus skin melanoma), NCI-H460 (human non-small
More informationNATURAL KILLER T CELLS EBOOK
08 April, 2018 NATURAL KILLER T CELLS EBOOK Document Filetype: PDF 90.41 KB 0 NATURAL KILLER T CELLS EBOOK Natural killer T cells (NK T cells) are a type of lymphocyte, or white blood cell. Natural killer
More information[Abstract] Objective: Investigate the effect of KLT on the expression of Fas/Apo-1, FasL and PCNA genes in renal carcinoma cell line (GRC-1).
Study on Effect of Kanglaite Injection(KLT) on the Expression of Fas/Apo-1, FasL and PCNA in Renal Carcinoma Cell Lines Wang Junjie, Sun Xinchen, Sheng Wenjiang, Yu Lizhang [Abstract] Objective: Investigate
More informationFoundations in Microbiology
Foundations in Microbiology Fifth Edition Talaro Chapter 15 The Acquisition of Specific Immunity and Its Applications Chapter 15 2 Chapter Overview 1. Development of the Dual Lymphocyte System 2. Entrance
More informationReprogramming Tumor Associated Dendritic Cells for Immunotherapy
Reprogramming Tumor Associated Dendritic Cells for Immunotherapy Edgar Engleman, M.D. Professor of Pathology and Medicine Stanford University Disclosures: Founder of Dendreon, a biotechnology company that
More informationHistocompatibility antigens
Histocompatibility antigens Tuesday 09 November 2010 Telegraph UK Livers grown in the laboratory could eventually solve organ transplant shortage. Made-to-measure organs for transplantation are a step
More informationExcerpt from MACS&more Vol 17 1/2016. Kenji Miki¹, Koji Nagaoka¹, Hermann Bohnenkamp², Takayuki Yoshimoto³, Ryuji Maekawa¹*, and Takashi Kamigaki⁴
Excerpt from MCS&more Vol 17 1/2016 Dendritic cells pulsed with induce both OV-specific CD4 + and CD8 + T cells and cause antitumor effects in a mouse model of lymphoma Kenji Miki¹, Koji Nagaoka¹, Hermann
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationDynamic analysis of lymphocyte subsets of peripheral blood in patients with acute self-limited hepatitis B
Vol.2, No.7, 736-741 (2010) doi:10.4236/health.2010.27112 Health Dynamic analysis of lymphocyte subsets of peripheral blood in patients with acute self-limited hepatitis B Bo Liu, Jun Li*, Yaping Han,
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationMcAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells
Effects of McAb and rhil-2 activated bone marrow on the killing and purging of leukemia cells X.C. Wei, D.D. Yang, X.R. Han, Y.A. Zhao, Y.C. Li, L.J. Zhang and J.J. Wang Institute of hematological research,
More informationStructure and Function of Antigen Recognition Molecules
MICR2209 Structure and Function of Antigen Recognition Molecules Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will examine the major receptors used by cells of the innate and
More informationChinese Journal of Cancer Reseatvh 9(4): Department of Immunology, Second Military Medical Universit3', Shanghai
Chinese Journal of Cancer Reseatvh 9(4):263-267. 1997 ANTITUMOR FFCT OF GRANULOCYT-MACROPHAG COLONY- STIMULATING FACTOR (GM-CSF)-GN NCODD VACCINIA MLANOMA ONCOLYSAT AND ITS IMMUNOLOGICAL MCHANISMS 1 Ju
More information4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo
Cellular & Molecular Immunology 379 Article 4-1BB (CD137) Ligand Enhanced Anti-Tumor Immune Response against Mouse Forestomach Carcinoma In Vivo Qiaoxia Li 1, Jun Ai 1, Zhenchuan Song 1, Jie Liu 2 and
More informationSUPPLEMENTARY INFORMATION
Complete but curtailed T-cell response to very-low-affinity antigen Dietmar Zehn, Sarah Y. Lee & Michael J. Bevan Supp. Fig. 1: TCR chain usage among endogenous K b /Ova reactive T cells. C57BL/6 mice
More informationBasic Immunology. Lecture 5 th and 6 th Recognition by MHC. Antigen presentation and MHC restriction
Basic Immunology Lecture 5 th and 6 th Recognition by MHC. Antigen presentation and MHC restriction Molecular structure of MHC, subclasses, genetics, functions. Antigen presentation and MHC restriction.
More informationConstruction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation
Construction of a hepatocellular carcinoma cell line that stably expresses stathmin with a Ser25 phosphorylation site mutation J. Du 1, Z.H. Tao 2, J. Li 2, Y.K. Liu 3 and L. Gan 2 1 Department of Chemistry,
More informationBlocking the expression of the hepatitis B virus S gene in hepatocellular carcinoma cell lines with an anti-gene locked nucleic acid in vitro
Blocking the expression of the hepatitis B virus S gene in hepatocellular carcinoma cell lines with an anti-gene locked nucleic acid in vitro Y.-B. Deng, H.-J. Qin, Y.-H. Luo, Z.-R. Liang and J.-J. Zou
More informationGeneral information. Cell mediated immunity. 455 LSA, Tuesday 11 to noon. Anytime after class.
General information Cell mediated immunity 455 LSA, Tuesday 11 to noon Anytime after class T-cell precursors Thymus Naive T-cells (CD8 or CD4) email: lcoscoy@berkeley.edu edu Use MCB150 as subject line
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationEffective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features
Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features Loretta Gammaitoni, Lidia Giraudo, Valeria Leuci, et al. Clin Cancer Res
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationElution of Tumoricidal Doses of Bortezomib from a Resorbable Cement Carrier
Elution of Tumoricidal Doses of Bortezomib from a Resorbable Cement Carrier Matthew Allen, Vet MB, PhD, Brittani Jones, BS. The Ohio State University, Columbus, OH, USA. Disclosures: M. Allen: 5; Johnson
More informationImmunity 101: The basics
As published in Research Update Research with Diamond V s Original line of products, including Original XPC, has consistently shown that these products influence the immune system of livestock and poultry.
More informationHelminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii. Ringworm fungus HIV Influenza
Helminth worm, Schistosomiasis Trypanosomes, sleeping sickness Pneumocystis carinii Ringworm fungus HIV Influenza Candida Staph aureus Mycobacterium tuberculosis Listeria Salmonella Streptococcus Levels
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationANTITUMOR EFFECT OF AN ANTI-ENDOTHELIAL CELL MONOCLONAL ANTIBODY BVE-1 ON SOLID TUMOR XENOGRAFT IN NUDE MICE
92 Chinese Journal of Cancer Research 11(2): 92 --96, 1999 ANTITUMOR EFFECT OF AN ANTI-ENDOTHELIAL CELL MONOCLONAL ANTIBODY BVE-1 ON SOLID TUMOR XENOGRAFT IN NUDE MICE LI Peiyu z}~r~]~-,1 YUAN Mei 3~'J~,
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Approved for public release; distribution unlimited
AD (Leave blank) Award Number: W81XWH-07-1-0345 TITLE: Second-Generation Therapeutic DNA Lymphoma Vaccines PRINCIPAL INVESTIGATOR: Larry W. Kwak, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Texas
More informationKentucky Lung Cancer Research Program. Cycle 6 Grant Abstracts
Kentucky Lung Cancer Research Program Cycle 6 Grant Abstracts Principal Investigator Paula Bates, Ph.D. J. Scott Bryson, Ph.D. Donald Cohen, Ph.D., Alan Kaplan, Ph.D. Edward Hirschowitz, M.D. Robert Mitchell,
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationSignificance of the MHC
CHAPTER 7 Major Histocompatibility Complex (MHC) What is is MHC? HLA H-2 Minor histocompatibility antigens Peter Gorer & George Sneell (1940) Significance of the MHC role in immune response role in organ
More informationAdaptive immune responses: T cell-mediated immunity
MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,
More informationChapter 17B: Adaptive Immunity Part II
Chapter 17B: Adaptive Immunity Part II 1. Cell-Mediated Immune Response 2. Humoral Immune Response 3. Antibodies 1. The Cell-Mediated Immune Response Basic Steps of Cell-Mediated IR 1 2a CD4 + MHC cl.
More informationBiochemistry of Cancer and Tumor Markers
Biochemistry of Cancer and Tumor Markers The term cancer applies to a group of diseases in which cells grow abnormally and form a malignant tumor. It is a long term multistage genetic process. The first
More informationAdvances in Cancer Immunotherapy
Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain
More informationSpecific immune cell therapy against ovarian cancer in vivo and in vitro
[Chinese Journal of Cancer 27:12, 494-499; December 2008]; 2008 Sun Yat-sen University Cancer Center Basic Research Paper Specific immune cell therapy against ovarian cancer in vivo and in vitro Xiao-Hong
More information7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit
7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit Item No. 600120 www.caymanchem.com Customer Service 800.364.9897 Technical Support 888.526.5351 1180 E. Ellsworth Rd Ann Arbor, MI USA TABLE OF CONTENTS
More informationOur T cell epitope test service offers you:
Our T cell epitope test service offers you: high throughput peptide discovery fast lead-finding maximum of epitopes in a minimum of blood saving effort and costs on developing your own platforms custom-made
More information7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit
7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit Catalog Number KA1293 96 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationPractical Solution: presentation to cytotoxic T cells. How dendritic cells present antigen. How dendritic cells present antigen
Christian Kurts Institutes of Molecular Medicine and Experimental Immunology University of Bonn, Germany - presentation and (CTL) activation - I presentation and CD4 + T cell (Th cell) activation Different
More informationLines of Defense. Immunology, Immune Response, and Immunological Testing. Immunology Terminology
Immunology, Immune Response, and Immunological Testing Lines of Defense If the First and Second lines of defense fail, then the Third line of defense is activated. B and T lymphocytes undergo a selective
More informationTITLE: Prostate Derived Ets Factor, an Immunogenic Breast Cancer Antigen. CONTRACTING ORGANIZATION: Roswell Park Cancer Institute Buffalo, NY, 14263
AD Award Number: W81XWH-05-1-0524 TITLE: Prostate Derived Ets Factor, an Immunogenic Breast Cancer Antigen PRINCIPAL INVESTIGATOR: Ashwani Sood, Ph.D. CONTRACTING ORGANIZATION: Roswell Park Cancer Institute
More informationA VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART
BIOE 301 LECTURE 10 MITALI BANERJEE A VACCINE FOR HIV HIV HAART Visit wikipedia.org and learn the mechanism of action of the five classes of antiretroviral drugs. (1) Reverse transcriptase inhibitors (RTIs)
More informationHLA and antigen presentation. Department of Immunology Charles University, 2nd Medical School University Hospital Motol
HLA and antigen presentation Department of Immunology Charles University, 2nd Medical School University Hospital Motol MHC in adaptive immunity Characteristics Specificity Innate For structures shared
More informationKit for assay of thioredoxin
FkTRX-02-V2 Kit for assay of thioredoxin The thioredoxin system is the major protein disulfide reductase in cells and comprises thioredoxin, thioredoxin reductase and NADPH (1). Thioredoxin systems are
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationHepatitis B virus X gene in the development of hepatocellular carcinoma. Citation Hong Kong Medical Journal, 2011, v. 17 n. 6, suppl. 6, p.
Title Hepatitis B virus X gene in the development of hepatocellular carcinoma Author(s) Ma, NF; Lau, SH; Hu, L; Dong, SS; Guan, XY Citation Hong Kong Medical Journal, 2011, v. 17 n. 6, suppl. 6, p. 44-47
More informationDevelopment of MVA-VLP Vectors for Cancer Immunotherapy
Farshad Guirakhoo, PhD fguirakhoo@geovax.com 678-384-7229 Development of MVA-VLP Vectors for Cancer Immunotherapy Executive Summary Cancer is the second most common cause of death in the US, exceeded only
More informationManipulation of the Immune Response - Immunomodulation -
Manipulation of the Immune Response - Immunomodulation - Janeway s Immunobiology, 9 th ed., 2017. Ivana Novak Nakir Immune system Immune system make components, cells and organs that act together to defend
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationMHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery
MHC Tetramers and Monomers for Immuno-Oncology and Autoimmunity Drug Discovery Your Partner in Drug Discovery and Research MHC Tetramer Background T-Cell Receptors recognize and bind to complexes composed
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationHDAC1 Inhibitor Screening Assay Kit
HDAC1 Inhibitor Screening Assay Kit Catalog Number KA1320 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay...
More informationT cell and Cell-mediated immunity
T cell and Cell-mediated immunity Lu Linrong ( 鲁林荣 ) PhD Laboratory of Immune Regulation Institute of Immunology Zhejiang University, it School of Medicine i Medical Research Building B815-819 Email: Lu.Linrong@gmail.com
More informationInternational Journal of Food Nutrition and Safety, 2012, 1(2): International Journal of Food Nutrition and Safety
International Journal of Food Nutrition and Safety, 2012, 1(2): 54-59 International Journal of Food Nutrition and Safety Journal homepage: www.modernscientificpress.com/journals/ijfns.aspx ISSN: 2165-896X
More informationT cell and Cell-mediated immunity
T cell and Cell-mediated immunity ( 第十章 第十二章第十二章 ) Lu Linrong ( 鲁林荣 ) PhD Laboratory of Immune Regulation Institute of Immunology Zhejiang University, School of Medicine Medical Research Building B815-819
More information